CD70+ malignanciesNishimoto et alADI-270
… and a dominant-negative TGFβRII receptor (dnTGFβRII) to target CD70+ malignancies, addressing immunosuppression and host-versus-graft rejection. …
1articles mentioning diseases
1disease mentions
1distinct diseases extracted
0%of mentions human-reviewed
Active filtersEntity: CD70+ malignancies ×
CD70+ malignancies
This disease is selected. Its supporting articles are shown below.